Elevara Medicines

Elevara Medicines is a clinical-stage biotechnology company developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases. The company offers a first-in-class oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes involved in the pathobiology of RA, enabling patients to achieve faster relief, higher remission rates, and safer long-term outcomes.